Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07534007) titled 'Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine Zoster in Vulnerable Population Receiving ImmunOmodulaNt Therapies' on April 10.

Study Type: Observational

Primary Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia

Condition: RZV Vaccine (Shingrix (R))

Recruitment Status: Recruiting

Date of First Enrollment: February 24, 2026

Target Sample Size: 150

Countries of Recruitment: Italy

To know more, visit https://clinicaltrials.gov/study/NCT07534007

Disclaimer: Curated by HT Syndication....